Group 4C: HER2-low, HER2-0 Breast Cancer; Antibody-Drug Conjugates; Targeted Therapies; Clinical Trials

Poster #TPS1120: Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in patients with HER2 low/ultra-low/null metastatic breast cancer.

Poster #1083: Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies.


Jun 13 2024


10:00 am - 11:30 am

Zoom Webinar